Results 161 to 170 of about 28,674 (272)

Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching. [PDF]

ACS Omega, 2019
Wang Y, Rakela S, Chambers JW, Hua ZC, Muller MT, Nitiss JL, Tse-Dinh YC, Leng F.   +7 more
europepmc   +1 more source

Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors [see comments] [PDF]

, 1996
PD Aplan, DS Chervinsky, Martin Stanulla, WC Burhans   +3 more
openalex   +1 more source

Gut Microbiome Dysbiosis is Associated With Human T‐Lymphotropic Virus Type 1 (HTLV‐1) Infection and Disease Progression to HTLV‐1‐Associated Myelopathy/Tropical Spastic Paraparesis: A Cross‐Sectional Study

Smart Medicine, Volume 5, Issue 1, February 2026.
We provide the first comprehensive analysis of changes in the gut bacteriome at different clinical stages of HTLV‐1 infection. HTLV‐1 infection is associated with a dysbiosis that includes reduced bacterial diversity and an inverted Firmicutes/Bacteroidetes ratio.
Lorena Abreu Fernandes, Ana Olivia de Souza, Youko Nukui, Rosa Maria Marcusso, Augusto César Penalva de Oliveira, Jorge Casseb, Patricia Bianca Clissa, Silas G. Villas‐Boas, Sabri Saeed Sanabani   +8 more
wiley   +1 more source

Assays for the Preferential Binding of Human Topoisomerase I to Supercoiled DNA

, 2009
Zheng Yang, James J. Champoux
openalex   +1 more source

A physical association between the human mutY homolog (hMYH) and DNA topoisomerase II-binding protein 1 (hTopBP1) regulates Chk1-induced cell cycle arrest in HEK293 cells [PDF]

, 2015
Se Hee Han, Soo-Hyun Hahm, An Hue Vy Tran, Ji Hyung Chung, Myoung‐Ki Hong, Hyun‐Dong Paik, Key‐Sun Kim, Ye Sun Han   +7 more
openalex   +1 more source

Data from Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity

, 2023
Andrea Emanuelli, Aurora P. Borroni, Liat Apel‐Sarid, Pooja A. Shah, Dhanoop Manikoth Ayyathan, Praveen Koganti, Gal Levy‐Cohen, Michael B. Blank   +7 more
openalex   +1 more source

Identification of prokineticin‐2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids

British Journal of Pharmacology, Volume 183, Issue 3, Page 491-504, February 2026.
Background and purpose Despite advances in immunotherapy, doxorubicin (Dox) chemotherapy is still the irreplaceable first‐line therapy for solid tumours such as breast cancer. However, chemotherapy resistance is the major limiting factor, requiring the use of high doses of Dox to achieve the anti‐tumour actions, often leading to severe side effects ...
Martina Vincenzi, Amin Kremic, Nathalie N. Tscheiller, Po‐Yen Hsu, Michael W. Y. Chan, Roberta Lattanzi, Canan G. Nebigil   +6 more
wiley   +1 more source

Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA. [PDF]

Genes (Basel), 2019
Morimoto S, Tsuda M, Bunch H, Sasanuma H, Austin C, Takeda S.   +5 more
europepmc   +1 more source

Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from the gram-positive model organism Streptococcus mutans

, 2019
Jesse A. Jones, Kirk E. Hevener
openalex   +1 more source

Supplementary Figure 5 from RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage

, 2023
Junko Iijima, Zhihong Zeng, Shunichi Takeda, Yoshihito Taniguchi   +3 more
openalex   +1 more source